A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...
On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...
Presented at ASCO 2021 by Dr. de Bono, gumelutamide (TAS3681) is a third generation androgen receptor antagonist targeting the ligand binding domain, but this agent also had minimal activity based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback